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Genetically predicted physical activity levels are associated
with lower colorectal cancer risk: a Mendelian randomisation
study
Xiaomeng Zhang1, Evropi Theodoratou1,2, Xue Li1,3, Susan M. Farrington4, Philip J. Law5, Peter Broderick5, Marion Walker4,
Yann C. Klimentidis6, Jessica M. B. Rees7, Richard S. Houlston5, Ian P. M. Tomlinson2, Stephen Burgess 8, Harry Campbell1,
Malcolm G. Dunlop 4 and Maria Timofeeva 4,9
BACKGROUND: We conducted a Mendelian randomisation (MR) study to investigate whether physical activity (PA) causes a
reduction of colorectal cancer risk and to understand the contributions of effects mediated through changes in body fat.
METHODS: Common genetic variants associated with self-reported moderate-to-vigorous PA (MVPA), acceleration vector
magnitude PA (AMPA) and sedentary time were used as instrumental variables. To control for confounding effects of obesity, we
included instrumental variables for body mass index (BMI), body fat percentage, waist circumference and arm, trunk and leg fat
ratios. We analysed the effect of these instrumental variables in a colorectal cancer genome-wide association study comprising
31,197 cases and 61,770 controls of European ancestry by applying two-sample and multivariable MR study designs.
RESULTS:We found decreased colorectal cancer risk for genetically represented measures of MVPA and AMPA that were additional
to effects mediated through genetic measures of obesity. Odds ratio and 95% confidence interval (CI) per standard deviation
increase in MVPA and AMPA was 0.56 (0.31, 1.01) and 0.60 (0.41, 0.88), respectively. No association has been found between
sedentary time and colorectal cancer risk. The proportion of effect mediated through BMI was 2% (95% CI: 0, 14) and 32% (95% CI:
12, 46) for MVPA and AMPA, respectively.
CONCLUSION: These findings provide strong evidence to reinforce public health measures on preventing colorectal cancer that
promote PA at a population level regardless of body fatness.
British Journal of Cancer (2021) 124:1330–1338; https://doi.org/10.1038/s41416-020-01236-2
BACKGROUND
Colorectal cancer is one of the most common cancers of
developed societies.1 Obesity is one of the risk factors for
colorectal cancer.2 Ready access to high-calorie foodstuffs
combined with a sedentary lifestyle means that obesity has
become a major public health problem in developed countries,
further contributing to increased colorectal cancer incidence.
Evidence from observational epidemiological studies is consistent
with the premise that increased physical activity (PA) reduces
colorectal cancer risk. Furthermore, the magnitude of the effect is
sufficient to be meaningful for the individual.3 An umbrella review of
22 anatomical cancer sites concluded that there is strong evidence
for a protective association between self-reported recreational PA
and colorectal cancer.4 In addition, a recent meta-analysis of 17
cohorts and 21 case–control studies found that occupational activity,
recreational activity, transport-related PA and reduced occupational
sedentary behaviour were each associated with lower colorectal
cancer risk.5 The estimated effects of increased recreational PA and
occupational sedentary behaviour for colon cancer risk were 0.80
(95% confidence interval (CI): 0.71, 0.89) and 1.44 (95% CI: 1.28, 1.62),
respectively, and for rectal cancer risk were 0.87 (95% CI: 0.75, 1.01)
and 1.02 (95% CI: 0.82, 1.28) respectively.5 Despite the strength of
such correlative evidence on the effect of PA on colorectal cancer
risk, causality cannot be ascribed by observational studies, since the
observed association could be due to confounding factors or
residual confounding. Furthermore, PA is routinely measured in
observational studies as a self-reported activity, and this may be
systematically overestimated.6
Given the lack of randomised clinical trials (RCTs) to formally
test the effect of a PA intervention on colorectal cancer risk, one
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approach is to apply Mendelian randomisation (MR) approaches to
test whether the association is causal. MR explores the effect of
the exposure (PA) on colorectal cancer risk through a genetic
instrumental variable.7 Since the instrumental variable is randomly
assorted at conception, it can overcome the aforementioned
shortcomings such as confounding effects. Common genetic
variants shown in genome-wide association studies (GWASs) to be
associated with PA can be used as instrumental variables for
various measures of PA. One recent MR study supports a causal
association between higher PA measured by accelerometer and
lower colorectal cancer risk.8 However, potential confounding or
mediating effect of body fatness was not taken into account.8
As the most commonly used measure of body fatness, body
mass index (BMI) is often considered as a proxy of overall body fat.
The body fat percentage measured by bioimpedance is another
proxy of overall body fat to compare with the results from BMI.
However, for people with the same overall body fat (i.e. BMI and
body fat percentage), body fat distribution changes with factors
such as sex, age, ethnicity, nutritional status and fitness training
level.9 Evidence shows that people with normal BMI but excess
trunk fat are at higher risk of metabolic diseases,10 while those
with a normal BMI but with excess leg fat are at lower myocardial
infarction risk.11 The effect of excess body fat (BMI, body fat
percentage, waist circumference and body fat distribution) on
colorectal cancer risk has been well described in observational2
and MR studies.12,13
Here, using MR approaches, we have investigated the observed
association between PA and colorectal cancer to establish, or
refute, causality. Further, we have tested whether the effects are
confounded by, or mediated through, measures of body fat. In
order to comprehensively assess the influence of body fat, we
employed measures of body fat including BMI, body fat
percentage, waist circumference and three types of body fat
distribution measured by bioimpedance.
METHODS
Genotype data resources for colorectal cancer case–control
genome-wide association analysis
We used genome-wide summary-level genotyping data imputed
to a merged reference panel comprising the 1000 Genome Project
and UK10K from a meta-analysis of 15 GWAS datasets14 from
populations of European ancestry (Supplementary Method and
Table S1). Briefly, the colorectal cancer GWAS meta-analysis
included the following GWASs: NSCCG, the SCOT study, SOCCS/
GS, SOCCS/LBC and UK Biobank GWAS, as well as ten previously
published GWASs: UK1, Scotland1, VQ58, CCFR1, CCFR2, COIN,
Finnish GWAS, CORSA, DACHS and Croatia. Standard quality-
control measures were applied to each GWAS and summary
statistic data from 31,197 cases and 61,770 controls were included
in the analyses.14 GWAS data from the UK Biobank was excluded
from the sensitivity analysis to avoid bias caused by sample
overlap between exposure and outcome datasets. All studies were
approved by respective ethics/institutional review committees, in
accordance with the Declaration of Helsinki. Participants of all the
included studies have signed the relevant consent forms.
Generation of genetic instruments
We implemented genetic instrumental variables for three
validated measures of continuous PA: self-reported moderate-to-
vigorous PA (MVPA), overall acceleration vector magnitude PA
(AMPA) and sedentary time. Instrumental variables for PA were
extracted from two GWASs that established associations between
common genetic variants (minor allele frequency ≥ 5%) and PA
(Table S2): (i) a meta-analysis of GWASs of 337,234 UK Biobank
participants on habitual PA;15 (ii) a GWAS of average acceleration
vector magnitude on 91,105 UK Biobank participants.16 All
summary-level statistics from the GWASs used in the current
work were restricted to CEU (northern and western European)
populations. Therefore, population stratification is not a potential
bias in our study. Data for the MVPA measure were derived from
self-reported questionnaires completed as part of the UK Biobank
dataset collected between 2006 and 2010.17 AMPA and sedentary
time were collected from a subset of 91,105 UK Biobank
participants wearing an accelerometer 7 days between 2013 and
2015.18 Details of MVPA, AMPA and sedentary time were
described in the Supplementary Methods. Klimentidis et al.15
detected eight single-nucleotide polymorphism (SNPs) for MVPA
at P < 5 × 10−9 (Table 1). Doherty et al.16 detected three SNPs at
P < 5 × 10−9 and five SNPs at P < 5 × 10−8 for AMPA and six SNPs
for the sedentary time at P < 5 × 10−8 (Table 1). The SNP-based
heritability estimate was 5% for MVPA, 21% for AMPA and 12.9%
for sedentary time.15,16
Several genetic variants associated with MVPA, AMPA and
sedentary time were previously found to be also associated with
the weight, BMI and arm/body/leg/trunk fat percentage (Table S3).
We included BMI, body fat percentage, waist circumference and
body fat distribution as indicators of obesity in our analysis. The
body fat distribution consists of arm fat ratio (AFR), trunk fat ratio
(TFR) and leg fat ratio (LFR) measured by segmental bio-electrical
Table 1. Description of instrumental variable (IV) for each measure.
Exposures No. of SNPs
for the IV
Variance explained




MVPA 7 0.0007 385,790 European Klimentidis et al.15 (29899525)
AMPA 5 0.002 91,105 European Doherty et al.16 (30531941)
AMPAb 3 0.001 91,105 European Doherty et al.16 (30531941)
Sedentary time 6 0.001 91,105 European Doherty et al.16 (30531941)
BMI 68 0.0232 322,154 European Locke et al.60 (25673413)
Body fat percentage 370 0.053 331,117 European Bycroft et al.61 (30305743)
Waist circumference 59 0.010 224,459 European Shungin et al.62 (25673412)
AFR 15 0.002 362,499 European Rask-Andersen et al.11 (30664634)
TFR 50 0.002 362,499 European Rask-Andersen et al.11 (30664634)
LFR 46 0.002 362,499 European Rask-Andersen et al.11 (30664634)
GWAS genome-wide association study, MVPA self-reported moderate-to-vigorous physical activity, AMPA acceleration vector magnitude physical activity, SNP
single-nucleotide polymorphism, IV instrumental variable, BMI body mass index, AFR arm fat ratio, LFR leg fat ratio, TFR trunk fat ratio.
aR2 was estimated base on the formula: 2 ´ EAF ´ ð1 EAFÞ ´ β2 .
bThreshold at P < 5 × 10−9.
Genetically predicted physical activity levels are associated with lower. . .














impedance (sBIA). The information about instrumental variables
for measures of body fatness can be found in Supplementary
Method, Table 1 and Fig. 1. The threshold of linkage disequili-
brium (LD) was set as R2 > 0.2. Due to the limited variance
explained by the MVPA SNPs, and the fact that the inverse
variance-weighted, MR-Egger and MR-Robust methods can
incorporate correlation between variants, we included all the
SNPs to generate instrumental variable and added correlation
matrix into these analyses (available in R package ‘MendelianRan-
domization’). We excluded rs149943 from the median-based
method because of LD (r2= 0.35) with rs3094622.
Two-sample MR
Having determined the effect estimates of SNPs on PA and each
measure of body fat from GWASs (Table 1), we tested the effects
of these SNPs on colorectal cancer risk using genome-wide data
from our previous colorectal cancer GWAS meta-analysis.14 The
causal effects and the corresponding standard errors of exposures
on colorectal cancer were calculated by using the random-effect
inverse variance-weighted method.19 We then evaluated the
heterogeneity among the causal effects of each variant (Cochran’s
Q statistic). P values < 0.10 were considered indicative of
significant heterogeneity.20
Multivariable MR
We applied multivariable MR21 to elucidate the causal relationship
between PA and colorectal cancer while keeping measures of body
fatness constant. First, we analysed the beta–beta correlations of
SNP effects for each exposure through Pearson’s correlation
coefficient analysis, including significant SNPs of all measures of
PA and body fatness. Next, we ran multivariable MR for measures
of PA that significantly associated with colorectal cancer risk in the
two-sample MR by adding measures of body fatness that
significantly associated with colorectal cancer risk in the two-
sample MR as covariates. In total, eight models were fitted (Fig. 1).
All SNPs associated with each trait were included to generate
instrumental variables for each model (Fig. 1). The pairwise LD
threshold between all of these SNPs was set at R2 > 0.2.
The rationale of the study design is shown in Fig. 1.
Sensitivity analysis
We applied a variety of sensitivity analyses testing different MR
assumptions.22 Specifically, we performed MR-Pleiotropy Residual
Sum and Outlier (MR-PRESSO),23 MR-Robust,24 MR-Egger,25 leave-
one-out method,26 mode-based estimate27 and the median-based
method.28 MR-Robust applies MM-estimation (modified
maximum-likelihood estimation) with Tukey’s bisquare function,
which efficiently limits the contribution of outliers.24 MR-Egger
was applied to explore any potential bias introduced by
pleiotropy. In particular, when the intercept of MR-Egger differs
from zero (at p < 0.05), then either directional pleiotropy is
indicated or the InSIDE assumption is violated.25 We also applied
the mode-based estimate, which works well when most estimates
of identical individual-instrument causal effects are derived from
valid instrumental variables and the weighted median-based
method, which allows for 50% of invalid weights.27,28
MR-PRESSO was applied to identify horizontal pleiotropic
outliers.23 When both MR-PRESSO and leave-one-out method
indicated an outlier, we took the analysis after removing the outlier
as our main analysis. Two-sample MR estimates can be biased
when samples between exposure and outcome GWASs over-
lapped.29 To minimise the risk of this bias, we performed sensitivity
analysis after excluding UK Biobank cohort participants from
colorectal cancer GWAS meta-analysis. In addition, we checked the
GWAS Catalogue30,31 (https://www.ebi.ac.uk/gwas/home, accessed
on 2 February 2020) and PhenoScanner32,33 (http://www.
phenoscanner.medschl.cam.ac.uk/, accessed on 2 February 2020)
to determine whether the PA instrumental variables were
associated with other traits, consistent with pleiotropic effects.
For all MR analyses, the P value threshold was set at 0.05. All
statistical analyses were performed on R v3.6.1 with packages
‘MendelianRandomization’ and ‘TwoSampleMR’.26,34
Power calculation
The non-centrality parameter-based approach was applied to
estimate the power of this study.35 The R2 (the variance explained
by each genetic instrument) was estimated by the following
formula: 2 ´ EAF ´ 1 EAFð Þ ´ β2 and F-statistic F ¼ R2 ´ ðN 
2Þ=ð1 R2Þ was applied to estimate the strength of genetic
Measures of physical activity
Instrumental variable selection for exposures
Two-sample Mendelian randomisation analysis: effects of physical activity and measures of body fatness on colorectal cancer risk
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P < 5 × 10-8, MAF ≥ 5%, LD < 0.2, removed outliers
detected by MR-PRESSO and leave-one-out method
P < 5 × 10-8, MAF ≥ 5%, LD < 0.2, (LD < 0.01 for body fat percentage), removed outliers
detected by MR-PRESSO and leave-one-out method
Measures of body fatness
Exposures that significantly associated with colorectal cancer risk in the two -sample Mendelian randomisation analyses












Fig. 1 Schematic representation of the study design. MAF minor allele frequency, LD linkage disequilibrium, MVPA self-reported moderate-
to-vigorous physical activity, AMPA acceleration vector magnitude physical activity, BMI body mass index.
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instrument,36,37 where EAF is effect allele frequency, beta is the
effect size of instrumental variables per standard deviation (SD)
change of PA and N is the sample size of PA GWAS. The MVPA-,
AMPA- and sedentary time-related variants explained ~0.07%,
0.2% and 0.1% of the phenotypic variance, respectively. We fixed
the type I error at α < 0.05 and listed the effect estimates that
could be detected for each SD increase of the PA time. We
required 80% power to detect any effects. Effect sizes that can be
detected with the power of 0.8, as well as F-statistics for
instrumental variables are presented in Table S4. The F-statistic
for all the analyses did not indicate weak instruments (F > 10).
RESULTS
Two-sample MR
The MR result indicated a decreased colorectal cancer risk through
the effect of MVPA. The odds ratio (OR) for inverse variance-
weighted MR was 0.56 for colorectal cancer risk per 1 SD increase
of MVPA (95% CI: 0.31, 1.01) (Figs. 2 and S1) and each sensitivity
analysis method generated similar effect estimates (Table S5). The
intercept of MR-Egger regression test did not identify any
horizontal pleiotropy and/or violation of the InSIDE assumption
(P= 0.75) and the Q-statistic did not indicate heterogeneity (P=
0.56). After removing the UK Biobank data case–control study
(4800 cases and 20,289 controls) from the outcome population,
the CI of effect sizes was wider (Table S5).
Implementing the MR-PRESSO and leave-one-out methods
highlight rs429358 as an outlier (Fig. S2). This SNP maps to the
APOE gene and showed the strongest association with PA. It is
also associated with multiple traits, including total cholesterol,
low-density lipoprotein cholesterol, triglyceride and Alzheimer’s
disease.38,39 This finding was supported by searching from GWAS
Catalogue and PhenoScanner (Table S3). Therefore, we generated
the instrumental variable by using seven SNPs for MVPA after
removing rs429358. The effect sizes of the seven MVPA SNPs with
MVPA and with colorectal cancer were presented in Table S6.
Evidence for a causal association was detected between AMPA
and colorectal cancer risk by using both five SNPs at P < 5 × 10−8
and three SNPs at P < 5 × 10−9 as genetic instruments (Fig. 2). In
particular, the ORs of inverse variance-weighted MR were 0.60
(95% CI: 0.41, 0.88) and 0.54 (95% CI: 0.35, 0.86) for each genetic
instrument (Figs. 2 and S1). All sensitivity analyses showed a
similar effect size of the association between AMPA and colorectal
cancer risk (Table S5). The Q-statistic suggested no heterogeneity
(P= 0.34 and 0.35, respectively) and the intercept of MR-Egger
suggested no pleiotropy. Removing UK Biobank colorectal cancer
GWAS from the outcome populations narrowed the CIs of the
effect sizes (Table S5). No association was detected between
sedentary time and colorectal cancer risk and no pleiotropy or
heterogeneity was indicated (Fig. 2 and Table S5). The effect
estimates for each instrumental variable on AMPA and colorectal
cancer or sedentary time and colorectal cancer were listed in
Table S6.
Two-sample MR on the associations between measures of body
fatness and colorectal cancer risk, as well as the effect estimates of
each SNP on exposures were listed in Table S7–10. BMI, body fat
percentage, waist circumference and AFR were significantly
associated with increased colorectal cancer risk, with OR (95%
CI) 1.24 (1.11, 1.39), 1.14 (1.03, 1.25), 1.19 (1.04, 1.36) and 1.50 (1.17,
1.93), respectively (Fig. 2). We did not observe any significant
associations between TFR or LFR and colorectal cancer risk.
Multivariable MR
Instrumental variables for BMI, waist circumference and AFR
were highly correlated as their correlation coefficients (r) range
from 0.67 to 0.79 (Fig. 3). Body fat percentage was positively
correlated with BMI (r= 0.13), waist circumference (r= 0.41), AFR
(r= 0.33) and TFR (r= 0.16). LFR and TFR were highly inversely
MVPA
Exposure P OR (95% Cl)





























Random effect IVW: OR (95% Cl)
1.5 2
Fig. 2 Forest plot of two-sample Mendelian randomisation studies exploring associations between exposures to colorectal cancer risk.
MVPA self-reported moderate-to-vigorous physical activity, AMPA acceleration vector magnitude physical activity at P < 5 × 10−8, AMPA*
acceleration vector magnitude physical activity at P < 5 × 10−9, BMI body mass index, OR odds ratio, CI confidence interval, IVW inverse
variant-weighted method, P P value for random effect IVW result.
Genetically predicted physical activity levels are associated with lower. . .
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correlated (r=−0.90). MVPA and AMPA were positively correlated
with each other (r= 0.16) and negatively correlated with
sedentary time (r=−0.23 and −0.42 respectively). The three
measures of PA were not correlated with colorectal cancer risk.
We estimated the direct effect of MVPA and AMPA and four
different measures of obesity and overweight on colorectal cancer
risk by applying the multivariable MR method (Table 2). The direct
effect sizes (OR) of MVPA or AMPA on colorectal cancer when BMI
was kept constant were 0.56 (95% CI: 0.36, 0.89) and 0.70 (95% CI:
0.52, 0.96), respectively. The direct effect sizes (OR) of BMI on
colorectal cancer when MVPA or AMPA was kept constant were
1.24 (95% CI: 1.12, 1.37) and 1.22 (95% CI: 1.09, 1.36), respectively.
There was no statistically significant heterogeneity and MR-Egger
did not indicate a significant pleiotropy effect. Compared to the
effect estimates from two-sample MR, the estimated CIs of the two
types of PA from multivariable MR became much wider, while the
BMI effects were not affected (Table 2 and Fig. 2). Results from
two-step network MR also indicated a partial mediation effect of
BMI on the PA-colorectal cancer association (Table S11).
The direct effect sizes (OR [95% CI]) of MVPA or AMPA on
colorectal cancer when AFR was kept constant were 0.58 (0.33,
1.02) and 0.64 (0.45, 0.92), respectively. The direct effect sizes of
AMPA on colorectal cancer when waist circumference was kept
constant were 0.61 (0.39, 0.97), while no association observed for
MVPA after adjusting for waist circumference. The associations
between MVPA or AMPA and colorectal cancer risk disappeared
when keeping body fat percentage constant.
Based on the total effect estimates from two-sample MR and
direct effect estimates from multivariable MR, we evaluated the
proportion of effects of PA on colorectal cancer risk mediated
through measures of body fat. The attenuated direct effects
indicated that part of the effects of the two measures of PA on
colorectal cancer was mediated through BMI or AFR. AMPA also
can affect colorectal cancer risk through waist circumference. For
the effects of MVPA and AMPA on colorectal cancer risk, the
proportion mediated through BMI was 2% (95% CI: 0, 14) and 32%
(95% CI: 12, 46), respectively, while the proportion mediated
through AFR was 8% (95% CI: 0, 16) and 14% (95% CI: 0, 35),
respectively (Fig. 4). The proportion of effects mediated through
waist circumference was 5% (95% CI: 0, 22) for AMPA (Fig. 4).
DISCUSSION
Colorectal cancer is a common cancer with appreciable morbidity
and mortality. Prospective cohort, case–control, and cross-
sectional observational studies support an inverse association
between PA and colorectal cancer risk.40–42 The association
between AMPA and colorectal cancer risk has been reported in
a previous MR study.8 However, the mechanism(s) through which
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Fig. 3 Genetic correlation coefficient between each covariate. MVPA self-reported moderate-to-vigorous physical activity, AMPA
acceleration vector magnitude physical activity, BMI body mass index, CRC colorectal cancer, AFR arm fat ratio, LFR leg fat ratio, TFR trunk
fat ratio.
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relative role of body weight and distribution in this association.
Applying two-sample and multivariable MR approaches, we used
genetic variants from large GWAS as instruments to explore
whether the apparent beneficial effects of three measures of PA
(MVPA, AMPA and sedentary time) on colorectal cancer risk are
mediated through body fatness. Our results show that both lower
MVPA and AMPA increase colorectal cancer risk, both indepen-
dently and through body fatness. In line with our findings, a meta-
analysis has indicated that PA is associated with colorectal cancer
risk in both high and low BMI groups.43
It is important to note that we found that increasing PA causes
decreased colorectal cancer risk independent of measures of
obesity and body fat distribution. One SD of MVPA is ~4.96
metabolic equivalent task (MET)-h/day. MET is an objectively
measured ratio of energy expenditure relative to the mass of a
person when performing PA compared to sitting quietly. Although
there is no standard method to transform milli-gravities (accel-
erometer measurement units) to energy expenditure, each SD of
AMPA was 8.14 milli-gravities (or 0.08 m/s2), which approximates
to 3 MET-h/day.18 For each SD increase in MVPA or AMPA,
colorectal cancer risk decreased by 44% and 40%, respectively.
These estimates imply that if individuals replace daily sedentary
behaviour with 20–90min of MVPA or with 13–60min accumu-
lated MVPA, their risk of colorectal cancer will decrease by 40%
(Table S12).44 In our study, MVPA estimated a longer time
spending on PA compared to the estimation by AMPA to achieve
a similar benefit of colorectal cancer risk, which is consistent with
the existing evidence that MVPA tends to overestimate time
engaged in PA in the general population.45 Part of the decreased
effect on colorectal cancer risk (2% [95% CI: 0, 14] and 8% [95% CI:
0, 16] for MVPA and 32% [95% CI: 12, 46] and 14% [95% CI: 0, 35]
for AMPA) was mediated through the effects of BMI and AFR,
respectively. Since the genetic instrument of MVPA is weaker
compare to AMPA, the BMI and AFR mediation effect for MVPA
may be underestimated.46
Diverse biological mechanisms have been proposed to explain
the observed inverse association between PA and colorectal
cancer. These include beneficial effects on bowel transit time,47
immune system reactions,48 metabolisms of bile acid, better
insulin sensitivity49 and the reduction of prostaglandin E2 levels in
colonic mucosa.50 Evidence from RCTs supports that PA can
reduce the bowel transit time and therefore reduce the time of
contact between carcinogens and colonic mucosa.47 The decrease
of prostaglandin E2 synthesis may also promote intestinal
peristalsis and hence reduce transit time.51 Besides, prostaglandin
E2 can promote tumour generation directly or through its
multifaceted effects on inflammation.52 PA also results in a lower
concentration of bile acid, which is an essential mediator of the
cholesterol mechanism and the lower bile acid concentration is
associated with lower blood triglycerides.53 The effect between PA




OR (95% CI) P Pint
a Phet
b OR (95% CI) P Pint
a Phet
b
Model 1 (AMPA+ BMI)
AMPA 0.70 (0.52, 0.96) 0.02 / 0.15 0.71 (0.46, 1.10) 0.13 0.95 0.13
BMI 1.22 (1.09,1.36) 4.65E – 04 1.01 (0.83, 1.23) 0.001
Model 2 (AMPA+ body fat percentage)
AMPA 0.86 (0.67, 1.10) 0.24 / 9.74E – 13 0.83 (0.59, 1.15) 0.26 0.70 8.01E – 13
Body fat percentage 1.10 (0.98, 1.24) 0.10 1.11 (0.98, 1.25) 0.09
Model 3 (AMPA+waist circumference)
AMPA 0.61 (0.39, 0.97) 0.04 / 0.05 0.61 (0.39, 0.97) 0.04 0.26 0.05
Waist circumference 1.21 (1.07, 1.36) 0.003 1.21 (1.07, 1.36) 0.003
Model 4 (AMPA+AFR)
AMPA 0.64 (0.45, 0.92) 0.02 / 0.35 0.52 (0.32, 0.84) 0.01 0.23 0.49
AFR 1.46 (1.09, 1.97) 0.01 1.47 (1.15, 1.89) 0.002
Model 5 (MVPA+ BMI)
MVPA 0.56 (0.36, 0.89) 0.01 / 0.22 0.58 (0.29, 1.15) 0.12 0.91 0.19
BMI 1.24 (1.12, 1.37) 7.67E – 5 1.24 (1.11, 1.38) 1.32E – 4
Model 6 (MVPA+ body fat percentage)
MVPA 0.84 (0.56, 1.26) 0.41 / 3.00E – 12 0.60 (0.33, 1.06) 0.08 0.10 5.36E – 12
Body fat percentage 1.12 (1.02, 1.24) 0.02 1.13 (1.02, 1.25) 0.02
Model 7 (MVPA+waist circumference)
MVPA 0.70 (0.42, 1.17) 0.18 / 0.05 0.64 (0.30, 1.34) 0.24 0.73 0.05
Waist circumference 1.19 (1.05, 1.34) 0.01 1.20 (1.05, 1.36) 0.01
Model 8 (MVPA+ AFR)
MVPA 0.58 (0.33, 1.02) 0.06 / 0.50 0.44 (0.20, 0.93) 0.03 0.27 0.52
AFR 1.39 (1.09, 1.79) 0.01 1.42 (1.10, 1.82) 0.01
MVPA self-reported moderate-to-vigorous physical activity, AMPA acceleration vector magnitude physical activity, BMI body mass index, AFR arm fat ratio, OR
odds ratio, CI confidence interval, IVW inverse variance-weighted, P P value for the effect estimate.
aPint: P value for the intercept of MR-Egger’s test.
bPhet: P value of χ
2 Q test for heterogeneity.
Genetically predicted physical activity levels are associated with lower. . .
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and colorectal cancer risk could be through these pathways,
although none of the genetic variants included as an instrumental
variable for PA was located within genes involved in indicators of
above-mentioned metabolism pathways. In addition, regular
moderate PA may have a benefit on natural cytotoxicity and T-
lymphocyte proliferation, on reducing the production of pro-
inflammatory cytokines and on increasing the count of T cells, B
cells and immunoglobulins.48
Strengths and limitations
One of the strengths of this study was that we explored both
subjective and objective measures of PA (MVPA, AMPA and
sedentary time). Previous studies showed that there are dis-
crepancies between MVPA and AMPA.54 Compared to MVPA
where recall and reporting bias are problematic, AMPA explains
44–47% variance of energy expenditure.55 MVPA tends to
overestimate time engaged in PA in the general population.45
Nevertheless, MVPA is commonly used in epidemiological and
observational studies, because it is data that is readily collected
and inexpensive. Our results for MVPA and AMPA were consistent,
with both supporting a causal effect of PA in reducing cancer risk.
The confidence intervals for the effect estimates observed for
AMPA were appreciably narrower than for MVPA, suggesting the
possibility of recall bias, but the health-promoting effect of
actually wearing an accelerometer might also influence our
results.56 Nonetheless, our use of a variety of instrumental variable
methods provides new insight into the effect of PA on cancer risk.
Another main advantage of our study is that we have clarified the
association pathways among three measures of PA, different
measures of body fatness and colorectal cancer for the first time,
including the total effect and direct effect, as well as the
proportion of the indirect effect. Several measures of body fatness
have been considered in our study, BMI and body fat percentage
represent two different measures of total body fat while waist
circumference, AFR, TFR and LFR represent body fat in different
areas. In the two-sample MR study, BMI, body fat percentage,
waist circumference and AFR are associated with colorectal cancer
risk, which is consistent with the previous evidence.12,57 Based on
the results of multivariable MR, AMPA can affect colorectal cancer
risk both through and independent of BMI, waist circumference
and AFR, while MVPA can affect colorectal cancer risk both
through and independent of BMI and AFR. After adjusting for body
fat percentage, associations between AMPA or MVPA and color-
ectal cancer risk disappeared, which may be due to the high
heterogeneity introduced by using hundreds of SNPs as the
instrumental variable. Papdimitriou et al. performed an MR on PA
and CRC risk and they also considered the effects of BMI in the
sensitivity analysis. In the current study, we have expanded
previous work by additionally including genetic instruments for
measures of body fatness along with PA in multivariable MR.
We acknowledge that the study has several limitations. First,
although we derived instrumental variables from the largest
available GWAS for PA, the SNPs for self-reported PA explain only
0.07% of the variance in MVPA. However, the calculated F-statistic
(F-statistic= 273) reached a widely-accepted threshold level.37 As
a result, our analysis of MVPA was underpowered (<0.8). Second,
with a 21% SNP heritability for AMPA and 5% for MVPA, the low
variance of genetic instruments (AMPA: 0.2%; MVPA: 0.07%) may
imply that the current discovered SNPs cannot be considered as
powerful proxies for PA. Furthermore, although we applied the
most up-to-date MR methods, we cannot completely rule out any
potential horizontal pleiotropy until we know all biological
functions for each SNP. Third, in two-sample MR analysis, weak
instrument bias is in the direction of the null while the partial
overlapping data between exposure and outcome from UK
Biobank may bias against the null.29 However, the sensitivity
analysis by removing UK Biobank participants from the colorectal
cancer GWAS broadens the CI for association with MVPA while
narrowing the CI for AMPA slightly. The overall results did not
change. Fourth, sBIA is not a perfect method to measure body fat
distribution. However, the correlation between body fat measured
by sBIA and MRI is ~0.858 and there is no available GWAS with
enough power on MRI or DEXA measured body fat distribution or
body fat percentage available. Fifth, because we do not have
access to individual-level data we did not perform stratified
analysis by gender or tumour site, even though evidence from a
European multinational cohort study showed that PA was
associated with proximal colon cancer and distal colon cancer
risk but not with rectal cancer risk.59 Hence, we may have
underestimated the effect of PA on colonic cancer risk in our
dataset by including rectal cancer. Finally, all analyses were
















AMPA vs AFR AMPA vs BMI AMPA vs WC MVPA vs AFR MVPA vs BMI
Fig. 4 Proportion estimates through BMI and body fat composition. BMI body mass index, MVPA self-reported moderate-to-vigorous
physical activity, AMPA acceleration vector magnitude physical activity, AFR arm fat ratio, WC waist circumference, AMPA vs AFR the
proportion of effects of AMPA on colorectal cancer risk mediated through AFR, AMPA vs BMI the proportion of effects of AMPA on colorectal
cancer risk mediated through BMI, AMPA vs WC the proportion of effects of AMPA on colorectal cancer risk mediated through WC, MVPA vs
AFR: the proportion of effects of AMPA on colorectal cancer risk mediated through AFR, MVPA vs BMI the proportion of effects of AMPA on
colorectal cancer risk mediated through BMI.
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derived from the GWAS on individuals of European ancestry,
which may impact the generalisability of our findings to non-
European populations.
CONCLUSIONS
The results of this study establish a causal role of both subjectively
and objectively measured PA in colorectal cancer risk, indepen-
dent of the obesity and body fat distribution. Our results suggest
that promoting and facilitating exercise could result in a decrease
in colorectal cancer incidence, regardless of individuals’ weight or
body fat distribution.
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